Key clinical point: A retrospective study suggests pregnancy after breast cancer is safe in BRCA-mutated patients.
Major finding: In a case-control analysis, pregnant patients had better disease-free survival than nonpregnant patients (hazard ratio, 0.71; P = .045), and there was no significant difference in overall survival between the pregnant and nonpregnant cohorts (HR, 0.86; P = .65).
Study details: Retrospective study of 1,252 patients diagnosed with stage I-III breast cancer and BRCA1/2 mutations.
Disclosures: The speaker disclosed a relationship with Teva.
Lambertini M et al. ASCO 2019, Abstract 11506.